BOTHELL, Wash.--(BUSINESS WIRE)--Aug. 9, 2006--Sonus Pharmaceuticals, Inc. (NASDAQ:SNUS) today reported second quarter financial results and updated its progress on 2006 objectives, including the development of TOCOSOL(R) Paclitaxel, the Company's lead oncology drug candidate, and TOCOSOL Camptothecin, Sonus' second oncology product candidate.